Literature DB >> 10411923

Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness.

Y Kang1, M Melo, E Deng, R Tisch, M El-Amine, D W Scott.   

Abstract

IgG molecules can be highly tolerogenic carriers for associated antigens. Previously, we reported that recipients of bone marrow or lipopolysaccharide-stimulated B-cell blasts, both of which were retrovirally gene-transferred with an immunodominant peptide in-frame with the variable region of a murine IgG heavy chain, were rendered profoundly unresponsive to that epitope. To further investigate whether tolerance to larger molecules can be achieved via this approach and whether the IgG scaffold is important for induction and maintenance of immunological tolerance, we engineered two retroviral constructs encoding the cI lambda repressor (MBAE-1-102 and MBAE-1-102-IgG) for gene transfer. Our results show that recipients of bone marrow or peripheral B cells, transduced with the MBAE-1-102-IgG recombinant, are hyporesponsive to p1-102. In addition, the self-IgG scaffold enhanced the induction and maintenance of such an immune hyporesponsiveness. Thus, our studies demonstrate that in vivo-expressed IgG heavy chain fusion protein can be processed and presented on the appropriate MHC class II, resulting in hyporesponsiveness to that antigen and offering an additional therapeutic approach to autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411923      PMCID: PMC17564          DOI: 10.1073/pnas.96.15.8609

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  T cell epitope selection: dominance may be determined by both affinity for major histocompatibility complex and stoichiometry of epitope.

Authors:  W F Li; M D Fan; C B Pan; M Z Lai
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

2.  B cells turn off virgin but not memory T cells.

Authors:  E J Fuchs; P Matzinger
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

Review 3.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy.

Authors:  D L Mueller; M K Jenkins; R H Schwartz
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

Review 5.  Dominance and crypticity of T cell antigenic determinants.

Authors:  E E Sercarz; P V Lehmann; A Ametani; G Benichou; A Miller; K Moudgil
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

6.  Murine MHC polymorphism and T cell specificities.

Authors:  S Roy; M T Scherer; T J Briner; J A Smith; M L Gefter
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

7.  Long-term expression of a T-cell receptor beta-chain gene in mice reconstituted with retrovirus-infected hematopoietic stem cells.

Authors:  J Kang; J Wither; N Hozumi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen.

Authors:  G Schönrich; F Momburg; M Malissen; A M Schmitt-Verhulst; B Malissen; G J Hämmerling; B Arnold
Journal:  Int Immunol       Date:  1992-05       Impact factor: 4.823

9.  Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.

Authors:  P V Lehmann; T Forsthuber; A Miller; E E Sercarz
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

10.  Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens.

Authors:  E E Eynon; D C Parker
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  18 in total

1.  Gene therapy in the treatment of autoimmune diseases.

Authors:  G C Tsokos; G T Nepom
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  CD8+ regulatory T cells are responsible for GAD-IgG gene-transferred tolerance induction in NOD mice.

Authors:  Renxi Wang; Gencheng Han; Lun Song; Jianan Wang; Guojiang Chen; Ruonan Xu; Ming Yu; Jiahua Qian; Beifen Shen; Yan Li
Journal:  Immunology       Date:  2008-06-20       Impact factor: 7.397

3.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

Authors:  Anne S De Groot; Leonard Moise; Julie A McMurry; Erik Wambre; Laurence Van Overtvelt; Philippe Moingeon; David W Scott; William Martin
Journal:  Blood       Date:  2008-07-25       Impact factor: 22.113

4.  Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.

Authors:  Yan Su; Robert Rossi; Anne S De Groot; David W Scott
Journal:  J Leukoc Biol       Date:  2013-05-31       Impact factor: 4.962

Review 5.  Inhibitors - cellular aspects and novel approaches for tolerance.

Authors:  D W Scott
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

6.  B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Mol Ther       Date:  2010-05-18       Impact factor: 11.454

7.  Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells.

Authors:  Xiaomei Wang; Babak Moghimi; Irene Zolotukhin; Laurence M Morel; Ou Cao; Roland W Herzog
Journal:  Mol Ther       Date:  2014-03-10       Impact factor: 11.454

8.  Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis.

Authors:  R K Agarwal; Y Kang; E Zambidis; D W Scott; C C Chan; R R Caspi
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

9.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

Authors:  Tie Chi Lei; David W Scott
Journal:  Blood       Date:  2005-03-15       Impact factor: 22.113

Review 10.  Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis.

Authors:  Shailesh R Satpute; Malarvizhi Durai; Kamal D Moudgil
Journal:  Semin Arthritis Rheum       Date:  2008-01-04       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.